Anti-malarial drug formulations and novel delivery systems: A review

Acta Tropica

Volumn 118, Issue 2, 2011, Pages 71-79

  Murambiwa, P ^a   Masola, B ^a   Govender, T ^a   Mukaratirwa, S ^a   Musabayane, C T ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Anti malarial drugs; Controlled release; Malaria; Novel formulation; Sustained release

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL; DAPSONE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; FOLIC ACID ANTAGONIST; HALOFANTRINE; LIPOSOME; MEFLOQUINE; NANOPARTICLE; NATURAL PRODUCT; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE PLUS SULFADOXINE; QUINIDINE DERIVATIVE; QUININE; QUININE DERIVATIVE;

DRUG; MALARIA; MORBIDITY; MORTALITY;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ANOREXIA; ATAXIA; ATRIOVENTRICULAR BLOCK; BLURRED VISION; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CERAMIC PROSTHESIS; CHEMOTHERAPY; CONCENTRATION RESPONSE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE TOXICITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LEUKOCYTE COUNT; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MENTAL DISEASE; MICROEMULSION; MOUTH ULCER; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PARALYSIS; PATIENT COMPLIANCE; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; RETICULOCYTE HEMOGLOBIN CONTENT; RETINA DISEASE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; THROMBOCYTOPENIA;

AFRICA; ANTIMALARIALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; HUMANS; MALARIA; PLASMODIUM; TREATMENT OUTCOME;

SUB-SAHARAN AFRICA;

EID: 79955477198     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.03.005     Document Type: Review

References (116)

1. Abdulla S., Sagara I., Borrmann S., D'Alessandro U., González R., Hame l.M., Ogutu B., Mårtensson A., Lyimo J., Maiga H., Sasi P., Nahum A., Bassat Q., Juma E., Otieno L., Björkman A., Beck H.P., Andriano K., Cousin M., Lefèvre G., Ubben D., Premji Z. Efficacy and safety of artemether/lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008, 372:1819-1827.
2. Achan J., Tibenderana J.K., Kyabayinze D., Wabwire-Mangen F., Kamya M.R., Dorsey G., D'Alessandro U., Rosenthal P.J., Talisuna A.O. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009, 339:b2763.
3. Adak T., Sharma V.P., Orlov V.S. Studies on the Plasmodium viva relapse pattern in Dehli, India. Am. J. Med. Hyg. 1998, 59(1):175-179.
4. Agrawal P., Gupta U., Jain N.K. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 2007, 28(22):3349-3359.
5. Akpalu A.K., Nyame P.K., Dodoo A.N.O. Amodiaquine-induced dystonic reactions: Case reports and implications for policy change in Ghana. Int. J. Risk Safety Med. 2005, 17:1-2.
6. Alkadi H.O. Antimalarial drug toxicity: A review. Chemotherapy 2007, 53(6):385-391.
7. Ashley E., Krudsood S., Phaiphun L., Srivilairit S., McGready R., Leowattana W., Hutagalung R., Wilairatana P., Brockman A., Looareesuwan L., Nosten F., White N.J. Dose optimisation randomized controlled studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multi-drug resistant falciparum malaria in Thailand. J. Infect. Dis. 2004, 190:1773-1782.
8. Ashley E.A., McGready R., Hutagalung R., Phaiphun L., Slight T., Proux S., Thwai K.L., Barends M., Looareesuwan S., White N.J., Nosten F. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis. 2005, 41:425-432.
9. Assefa A., Kassa M., Tadese G., Mohamed H., Animut A., Mengesha T. Therapeutic efficacy of Artemether/Lumefantrine (Coartem(R) against Plasmodium falciparum in Kersa, South West Ethiopia. Parasit. Vectors 2010, 3(1):1.
10. Baird J.K., Rieckmann K.H. Can primaquine therapy for vivax malaria be improved?. Trends Parasitol. 2003, 19(3):115-120.
11. Barennes H., Balima-Koussoube T., Nagot N., Charpentier J.C., Pussard E. Safety and efficacy of rectal compared with intramuscular quinine for the early treatment of moderately severe malaria in children: randomized clinical trial. Br. Med. J. 2006, 332(7549):1055-1057.
12. Barennes H., Pussard E., Mahaman Sani A., Clavier F., Kahiatani F., Granic G., Henzel D., Ravinet L., Verdier F. Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. Br. J. Clin. Pharmacol. 1996, 41(5):389-395.
13. Barennes H., Verdier F., Clavier F., Pussard E. Pharmacokinetics of Quinimax suppositories in children with malaria. Clin. Drug Invest. 1999, 17:287-291.
14. Bloland P.B. A contrarian view of malaria therapy policy in Africa. Am. J. Trop. Med. Hyg. 2003, 68(2):125-126.
15. Brasseur P., Guiguemde R., Diallo S., Guiyedi V., Kombila M., Ringwald P., Olliaro P. AmodiaquineAmodiaquine remains effective for treating uncomplicated malaria in West and Central Africa. Trans. R. Soc. Trop. Med. Hyg. 1999, 93:645-650.
16. Burgoine K.L., Bancone G., François Nosten F. The reality of using primaquine. Malaria Journal 2010 2010, 9:376.
17. Bzik D., Li W., Horii T., Inselburg J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:8360-8364.
18. Chandra S. Chloroquine delivery to erythrocytes in Plasmodium berghei-infected mice using antibody bearing liposomes as drug vehicles. J. Biosci. 2007, 16(3):137-144.
19. Chedgzoy P., Winckle G., Heard C.M. Triclosan: release from adhesive transdermal formulations and in vitro permeation across human epidermal membranes. Int. J. Pharm. 2002, 235(1-2):229-236.
20. Chimanuka B., Gabriëls M., Detaevernier M.R., Plaizier-Vercammen J.A. Preparation of beta-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria infected mice. J. Pharm. Biomed. Anal. 2002, 28(1):13-22.
21. Cox-Singh J., Davis T.M., Lee K.S., Shamsul S.S., Matusop A., Ratnam S., Rahman H.A., Conway D.J., Singh B. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin. Infect. Dis. 2008, 46:165-171.
22. Dierling A.M., Cui Z. Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy. Int. J. Pharm. 2005, 303(1-2):148-152.
23. Dorsey G., Njama D., Kamya M.R., Cattamanchi A., Kyabayinze D., Staedke S.G., Gasasira A., Rosenthal P.J. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomized trial. Lancet 2002, 360:2031-2038.
24. Duong S., Lim P., Fandeur T., Tsuyuoka R., Wongsrichanalai C. Importance of protection of anti-malarial combination therapies. Lancet 2004, 364(9447):1754-1755.
25. Dyson E.H., Proudfoot A.T., Prescott L.F., Heyworth R. Death and blindness due to overdose of quinine. Br. Med. J. 1985, 291(6487):31-33.
26. Falade C., Makanga M., Premji Z., Ortmann C.E., Stockmeyer M., de Palacios P.I. Efficacy and safety of artemether/lumefantrine (Coartem®) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2005, 99:459-467.
27. Fanello C.I., Karema C., Ngamije D., Uwimana A., Ndahindwa V., Van Overmeir C., Van Doren W., Curtis J., D'Alessandro U. A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone plus artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2008, 102(5):412-420.
28. Ferreras A., Pinilla I., Abecia E., Pajarín A.B., Honrubia F.M. Retinal toxicity following chloroquine therapy. Arch. Soc. Esp. Oftalmol. 2007, 82(2):103-108.
29. Gabriels M., Plaizier-Vercammen J. Physical and chemical evaluation of liposomes, containing artesunate. J. Pharm. Biomed. Anal. 2003, 31(4):655-667.
30. Galloway J.A., Chance R.E. Improving insulin therapy: achievements and challenges. Horm. Metab. Res. 1994, 26(12):591-598.
31. Garnham P.C.C., Bray R.S., Bruce-Chwatt L.J., Draper C.C., Killick-Kendrick R., Sergiev P.G., Tiburskaja N.A., Shute P.G., Maryon M. A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. Bull. World Health Org. 1975, 52(1):21-32.
32. Gasasira A.F., Dorsey G., Nzarubara B., Staedke S.G., Nassali A., Rosenthal P.J., Kamya M.R. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am. J. Trop. Med. Hyg. 2003, 68:127-132.
33. Giao P.T., de Vries P.J., Hung L.Q., Binh T.Q., Nam N.V., Kager P.A. CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. Trop. J. Med. Int. Health 2004, 9:209-216.
34. Glynne P., Salama A., Chaudhry A., Swirsky D., Lightstone L. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Am. J. Kid. Dis. 1999, 33:133-137.
35. Gorissen E., Ashruf G., Lamboo M., Bennebroek J., Gikunda S., Mbaruku G., Kager P.A. In vivo efficacy study of amodiaquine and sulfadoxine/pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Trop. Med. Int. Health 2000, 5:459-463.
36. Gottschall J., Elliot W., Lianos E., McFarland J.G., Wolfmeyer K., Aster R.H. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome -a new clinical entity. Blood 1991, 77(2):306-310.
37. Graff C.L., Pollack G.M. Functional evidence for p-glycoprotein at the nose- brain barrier. Pharm. Res. 2005, 22(1):86-93.
38. Green M.D., D'Souza M.J., Holbrook J.M., Wirtz R.A. In vitro and in vivo evaluation of albumin-encapsulated primaquine diphosphate prepared by nebulization into heated oil. J. Microencapsul. 2004, 21(4):433-444.
39. Hatz C., Soto J., Nothdurft H.D., Zoller T., Weitzel T., Loutan L., Bricaire F., Gay F., Burchard G.D., Andriano K., Lefèvre G., De Palacios P.I., Genton B. Treatment of acute uncomplicated falciparum malaria with artemether/lumefantrine in non-immune populations: a safety, efficacy and pharmacokinetic study. Am. J. Trop. Med. Hyg. 2008, 78:241-247.
40. Heard C.M., Monk B.V., Modley A.J. Binding of primaquine to epidermal membranes and keratin. Int. J. Pharm. 2003, 257(1-2):237-244.
41. Hung T.Y., Davis T.M., Ilett K.F., Karunajeewa H., Hewitt S., Denis M.B., Lim C., Socheat D. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 2004, 57:253-262.
42. Hung T.Y., Davis T.M., Ilett K.F. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2003, 791:93-101.
43. Hutagalung R., Paiphun L., Ashley E.A., McGready R., Brockman A., Thwai K.L., Singhasivanon P., Jelinek T., White N.J., Nosten F.H. A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malaria J. 2005, 22(4):46.
44. Illum L. Nasal drug delivery-possibilities, problems and solutions. J. Control. Release 2003, 87(1-3):187-198.
45. Jambou R., Legrand E., Niang M., Khim N., Lim P., Volney B., Ekala M.T., Bouchier C., Esterre P., Fandeur T., Mercereau-Puijalon O. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366(9501):1960-1963.
46. Jeans C.W., Heard C.M. A therapeutic dose of primaquine can be delivered across excised human skin from simple transdermal patches. Int. J. Pharm. 1999, 189(1):1-6.
47. Kaschula C.H., Egan T.J., Hunter R., Basilico N., Parapini S., Taramelli D., Pasini E., Monti D. Structure-activity relationships in 4 aminoquinoline antiplasmodials. The role of the group at the 7-position. J. Med. Chem. 2002, 45(16):3531-3539.
48. Klayman D.L., Ager A.L., Fleckenstein L., Lin A.J. Transdermal artelinic acid: an effective treatment for Plasmodium berghei-infected mice. Am. J. Trop. Med. 1991, 45:602-607.
49. Kokwaro G., Mwai L., Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Exp. Opin. Pharmacother. 2007, 8(1):75-94.
50. Kongpatanakul S., Chatsiricharoenkul S., Khuhapinant A., Atipas S., Kaewkungwal J. Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers. Int. J. Clin. Pharm. Ther. 2009, 47(9):579-586.
51. Kreidenweiss A., Kremsner P.G., Dietz K., Mordmüller B. In vitro activity of ferroquine (sar97193) is independent of chloroquine resistance in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 2006, 75(6):1178-1181.
52. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., Plowe C.V. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 2002, 185(3):380-388.
53. Kuranajeewa H.A., Manning L., Mueller I., Ilett K.F., Davis T.M. Rectal administration of artemisinin derivatives for the treatment of malaria. JAMA 2007, 297(21):2381-2390.
54. Legrand P., Mosqueira V., Loiseau P., Bories C., Barratt G. Long circulating nanocapsules: interest in the treatment of severe malaria with halofantrine. Ann. Pharm. Fr. 2003, 61(3):196-202.
55. Lin A.J., Ager A.L., Klayman A.L. Antimalarial activity of dihydroartemisinin derivatives by transdermal application. Am. Soc. Trop. Med. Hyg. 1994, 50(6):777-783.
56. Lu F., Lim C.S., Deok Hwa Nam D.H., Kim K., Lin K., Kim T.S., Lee H.W., Chen J.H., Wang Y., Sattabongkot J., Han E.T. Mutations in the antifolate-resistance-associated genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium vivax isolates from malaria-endemic countries. Am. J. Trop. Med. Hyg. 2010, 83(3):474-479.
57. Mayorga P., Deharo E., Puisieux F., Couarraze G. Interpretation and prediction of plasma levels of primaquine following transdermal delivery in Swiss mice. Int. J. Pharm. 1997, 155(1):99-107.
58. Mayorga P., Miltgen F., Coquelin F., Couarraze G. Rodent malaria prophylaxis by transdermal delivery of primaquine. Int. J. Parasitol. 1998, 28(8):1283-1285.
59. Mayorga P., Puisieux F., Couarraze G. Formulation study of a transdermal delivery of primaquine. Int. J. Pharm. 1996, 132(1-2):71-79.
60. Mugittu K., Abdulla S., Falk N., Masanja H., Felger I. Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies. Malaria J. 2005, 4(1):55.
61. Mulenga M., Malunga F., Bennett S., Thuma P.E., Shulman C., Fielding K., Alloueche A., Greenwood B.M. A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children. Trop. Med. Int. Health 2006, 11(11):1643-1652.
62. Musabayane C.T., Munjeri O., Matavire T.P. Transdermal delivery of chloroquine by amidated pectin hydrogel matrix patch in the rat. Renal Failure 2003, 25(4):525-534.
63. Musabayane C.T., Windle R.J., Forsling M.L., Balment R.J. Arginine vasopressin mediates the chloroquine induced increase in renal sodium excretion. Trop. Med. Int. Health 1996, 1(4):542-550.
64. Myat-Phone-Kyaw, Myint-Oo, Aung-Naing, Aye-Lwin-Htwe The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. Southeast Asian J. Trop. Med. Public Health 1994, 25(4):710-713.
65. Nair A., Reddy C., Jacob S. Delivery of a classical antihypertensive agent through the skin by chemical enhancers and iontophoresis. Skin Res. Technol. 2009, 15(2):187-194.
66. Ndesendo V.M., Meixner W., Korsatko W., Korsatko-Wabnegg B. Microencapsulation of chloroquine diphosphate by Eudragit RS100. J. Microencapsul. 1996, 13(1):1-8.
67. Newton P., Suputtamongkol Y., Teja-Isavadharm P., Pukrittayakamee S., Navaratnam V., Bates I., White N. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob. Agents Chemother. 2000, 44:972-977.
68. Nishi K.K., Jayakrishnan A. A Preparation and in vitro evaluation of primaquine-conjugated gum arabic microspheres. Biomacromolecules 2004, 5(4):1489-1495.
69. Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda M.M. Evidence of artemisinin-resistant malaria in western Cambodia; Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. N. Engl. J. Med. 2008, 359(24):2619-2620.
70. Nosten F., White N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 2007, 77(6):181-192.
71. Nwanyanwu O.C., Ziba C., Kazembe P., Chitsulo L., Willima J.J., Kumwenda N., Redd S.C. Efficacy of sulphadoxine/pyrimethamine for Plasmodium falciparum malaria in Malawian children under five years of age. Trop. Med. Int. Health 1996, 1:231-235.
72. Ogbonna A., Uneke C. Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: the efficacy, safety, resistance and policy implementation since Abuja 2000. Trans. R. Soc. Trop. Med. Hyg. 2008, 102(7):621-627.
73. Ogungbamigbe T.O., Ojurongbe O., Ogunro P.S., Okanlawon B.M., Kolawole S.O. Nigeria: efficacy of amodiaquine plus sulfadoxine-pyrimethamine and chloroquine plus chlorpheniramine for treatment. Mem. Inst. Oswaldo Cruz. 2008, 103(1):79-84.
74. Olliaro P., Nevill C., LeBras J., Ringwald P., Mussano P., Garner P., Brasseur P. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996, 348:1196-1201.
75. Olliaro P.L., Bloland P.B. Clinical and public health implications of antimalarial drug resistance. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery 2001, 65-83. Humana, Totowa, NJ. P. Rosenthal (Ed.).
76. Owais M., Varshney G.C., Choudhury A., Chandra S., Gupta C.M. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob. Agents Chemother. 1995, 39(1):180-184.
77. Patel V.A., Murthy R.S.R., Patel H.V. Formulation and in vitro characterization of ethyl cellulose microspheres containing chloroquine phosphate. J. Indian Pharm. 2006, 5(51):82-86.
78. Perkins N.C., Heard C.M. In vitro dermal and transdermal delivery of doxycycline from ethanol:migliol 840 vehicles. Int. J. Pharm. 1999, 190(2):155-164.
79. Petras J., Young G.D., Bauman R.A., Kyle D.E., Gettayacamin M., Webster H. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, the paramedian reticula nuclei, and perihypoglossal nuclei. Anat. Embryol. 2000, 20(5):383-397.
80. Phillips-Howard P.A., West L.J. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J. R. Soc. Med. 1990, 83:82-85.
81. Posner G.H., Paik I.H., Sur S., McRiner A.J., Borstnik K., Xie S., Shapiro T.A. Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J. Med. Chem. 2003, 46(6):1060-1065.
82. Rodrigues J.M., Croft S.L., Fessi H., Bories C., Devissaguet J.P. The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice. Trop. Med. Parasitol. 1994, 45(3):223-228.
83. Rytting E., Nguyen J., Wang X., Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Exp. Opin. Drug Deliv. 2008, 5(6):629-639.
84. Saparia B., Solanki A., Murthy R.S.R. Sustained release implants of chloroquine phosphate for possible use in chemoprophylaxis of malaria. Indian J. Exp. Biol. 2001, 39(9):902-905.
85. Saussine A., Loriot M.A., Picard C., Lecerf V., Landry J., Scheer I., Voicu S., Leenhardt A., Ducrocq G., Maubec E., Crickx B. Chloroquine cardiotoxicity in long term lupus therapy in two patients. Ann. Dermatol. Venereol. 2009, 136(6-7):530-535.
86. Sen A., Daly M.E., Hui S.W. Transdermal insulin delivery using lipid enhanced electroporation. Biochim. Biophys. Acta 2002, 1564(1):5-8.
87. Shanks G.D., Kain K.C., Keystone J.S. Malaria chemoprophylaxis in the age of drug resistance. II: Drugs that may be available in the future. Clin. Infect. Dis. 2001, 33(3):381-385.
88. Sharma A., Sharma U. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997, 154:123-140.
89. Shekalaghe S.A., ter Braak R., Daou M., Kavishe R., van den Bijllaardt W., van den Bosch S., Koenderink Jan B., Luty A.J.F., Whitty C.J.M., Drakeley C., Sauerwein R.W., Bousema T. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob. Agents Chemother. 2010, 54(5):1762-1768.
90. Singh K.K., Vingkar S.K. Formulation, anti-malarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int. J. Pharm. 2008, 347(1-2):136-143.
91. Siqueira-Batista R., Ramos Junior A.N., Pessanha B.S., Sforza-de Almeida M.P., Potsch D.F. Chloroquine and cardiac arrhythmia: case report. East Afr. Med. J. 1998, 75(2):117-119.
92. Sirsat R.A., Dasgupta A. Haematological complications of proguanil in a patient with chronic renal failure. Nephron 1997, 97(1):108.
93. Srivastava I.K., Vaidya A.B. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother. 1999, 43(6):1334-1339.
94. Staedke S.G., Kamya M.R., Dorsey G., Gasasira A., Ndeezi G., Charlebois E.D., Rosenthal P.J. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomized trial. Lancet 2001, 358:368-374.
95. Tafazoli S., O'Brien P.J. Amodiaquine-induced oxidative stress in a hepatocyte inflammation model. Toxicology 2009, 256(1-2):101-109.
96. Tarnchompoo B., Sirichaiwat C., Phupong W., Intaraudom C., Sirawaraporn W., Kamchonwongpaisan S., Vanichtanankul J., Thebtaranonth Y., Yuthavong Y. Development of 2,4- diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine resistant Plasmodium falciparum. J. Med. Chem. 2002, 45(6):1244-1252.
97. Tarning J., Lindegardh N., Annerberg A., Singtoroj T., Day N.P., Ashton M., White N.J. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 2005, 49:5127-5128.
98. Taylor W.R.J., White N.J. Antimalarial drug toxicity: a review. Drug Safety 2004, 27(1):25-61.
99. Touitou E., Waknine J.H., Godin B., Golenser J. Treatment of malaria in a mouse model by intranasal drug adminstration. Int. J. Parasitol. 2006, 6(14):1493-1498.
100. Van Dillen J., Custers M., Wensink A., Wouters B., van Voorthuizen T., Voorn W., Khan B., Muller L., Nevill C. A comparison of amodiaquine and sulfadoxine-pyrimethamine as firstline treatment of falciparum malaria in Kenya. Trans. R. Soc. Trop. Med. Hyg. 1999, 93:185-188.
101. van Vugt M., Looareesuwan S., Wilairatana P., McGready R., Villegas L., Gathmann I., Mull R., Brockman A., White N.J., Nosten F. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2000, 94(5):545-548.
102. van Vugt M.V., Wilairatana P., Gemperli B., Gathmann I., Phaipun L., Brockman A., Luxemburger C., White N.J., Nosten F., Looareesuwan S. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 1999, 60:936-942.
103. Vaziri A., Warburton B. Slow release of chloroquine phosphate from multiple taste-masked W/O/W multiple emulsions. J. Microencapsul. 1994, 11(6):641-648.
104. Vijaykadga S., Rojanawatsirivej C., Cholpol S., Phoungmanee D., Nakavej A., Wongsrichanalai C. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop. Med. Int. Health 2006, 11:211-219.
105. Wan Y.D., Zang Q.Z., Wang J.S. Studies on the antimalarial action of gelatin capsule of Artemisia annua. Zhonqquo ji shenq chonq xue yu ji shenq chonq bing za zhi 1992, 10(4):290-294.
106. Warrell D.A., Molyneux M.E., Beales P.F. Severe and complicated malaria. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:S1-S65.
107. Watkins W.M., Masobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans. R. Soc. Trop. Med. Hyg. 1993, 87(1):75-78.
108. Wen J., Mao H., Li W., Lin K.Y., Leong K.W. Biodegradable polyphosphoester micelles for gene delivery. J. Pharm. Sci. 2004, 93(8):2142-2157.
109. Wernsdorfer W.H., Landgraf B., Kilimali V.A., Wernsdorfer G. Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa. Acta Trop. 1998, 70:9-15.
110. Winstanley P.A., Breckenridge A.M. Currently important antimalarial drugs. Ann. Trop. Med. Parasitol. 1987, 81(5):619-627.
111. Winstanley P.A., Ward S., Snow R., Breckenridge A. Therapy Falciparum Malaria in Sub-Saharan Africa: from Molecule to policy. Clin. Microbiol. Rev. 2004, 17(3):612-637.
112. Winstanley P.A. Mefloquine: the benefits outweigh the risks Brit. J. Clin. Pharmacol. 1996, 42(4):411-413.
113. World Health Organization, 2006. Guidelines for the treatment of malaria (1st ed.). Report no WHO/HTM/MAL/2006.1108. World Health Organization, Geneva.
114. World Health Organization, 2008. World malaria report WHO/HTM/GMP/2008.1. WHO, Geneva.
115. Yong C.S., Sah H., Jahng Y., Chang H.W., Son J.K., Lee S.H., Jeong T.C., Rhee J.D., Baek S.H., Kim C.K., Choi H.G. Physicochemical characterization of diclofenac sodium-loaded poloxamer gel as a rectal delivery system with fast absorption. Drug Dev. Ind. Pharm. 2003, 29(5):545-553.
116. Zwang J., Ashley E.A., Karema C., D'Alessandro U., Smithuis F. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS ONE 2009, 4(7):e6358.